US approvals of high-risk medical devices are way down.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Device deal making is back in a big way, despite the munificence of venture funds.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.